Search

Your search keyword '"Tripp, Barbara"' showing total 3 results
Start Over Author "Tripp, Barbara" Publisher pergamon press
3 results on '"Tripp, Barbara"'

1. Centralizing care of cancer-associated thromboembolism: The Cleveland Clinic experience.

Author

Rabinovich E, Bartholomew JR, Wilks ML, Tripp BL, McCrae KR, and Khorana AA

Subjects
Aged, Ambulatory Care Facilities economics, Anticoagulants economics, Female, Health Care Costs, Humans, Male, Middle Aged, Recurrence, Venous Thromboembolism economics, Anticoagulants therapeutic use, Neoplasms complications, Venous Thromboembolism drug therapy, Venous Thromboembolism etiology
Published
2016
Full Text
View/download PDF

2. A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.

Author

Advani AS, Tiu R, Saunthararajah Y, Maciejewski J, Copelan EA, Sobecks R, Sekeres MA, Bates J, Rush ML, Tripp B, Salvado A, Noon E, Howard M, Jin T, Hsi E, Egorin MJ, Lim K, Cotta CV, Price C, and Kalaycio M

Subjects
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Benzamides, Cytarabine administration & dosage, Cytarabine adverse effects, Daunorubicin administration & dosage, Daunorubicin adverse effects, Female, Humans, Imatinib Mesylate, Leukemia, Myeloid, Acute metabolism, Male, Maximum Tolerated Dose, Middle Aged, Phosphorylation drug effects, Piperazines administration & dosage, Piperazines adverse effects, Pyrimidines administration & dosage, Pyrimidines adverse effects, Recurrence, STAT5 Transcription Factor metabolism, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Leukemia, Myeloid, Acute prevention & control, Proto-Oncogene Proteins c-kit
Abstract

The c-kit receptor is expressed in 95% of relapsed acute myeloid leukemias (AMLs) and mediates leukemic proliferation. We conducted a Phase 1 study of the c-kit inhibitor, imatinib mesylate (IM), in combination with cytarabine and daunorubicin (7+3) in c-kit+ relapsed AML. IM was dose escalated using a 3 by 3 design. Phosphorylated STAT5 was absent to minimally present in residual blasts on day 14 bone marrows. The maximum tolerated dose of IM was 300 mg. The dose-limiting toxicity was Grade 3-4 hepatic toxicity. The CR/CRp rate was 57%. Cytotoxic therapy that includes IM for relapsed AML is well-tolerated and effective., (Copyright © 2010 Elsevier Ltd. All rights reserved.)

Published
2010
Full Text
View/download PDF

3. Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML.

Author

Advani AS, Rodriguez C, Jin T, Jawde RA, Saber W, Baz R, Kalaycio M, Sobecks R, Sekeres M, Tripp B, and Hsi E

Subjects
Adolescent, Adult, Aged, Disease Progression, Disease-Free Survival, Female, Fluorescence, Humans, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute mortality, Male, Middle Aged, Retrospective Studies, Survival Rate, Flow Cytometry, Leukemia, Myeloid, Acute metabolism, Proto-Oncogene Proteins c-kit metabolism
Abstract

C-kit, a tyrosine kinase receptor, is expressed on most myeloid blasts and is thought to be important in the pathogenesis of AML. Activation of the c-kit receptor leads to phosphorylation and activation of downstream signaling proteins, which are important for cell survival and proliferation. Here, we discuss the prognostic impact of c-kit intensity, measured using the mean fluorescent index (MFI) in patients with newly diagnosed AML. On multivariate analysis, c-kit MFI>20.3 correlated with a decreased progression-free survival and overall survival, independent of known prognostic factors (age, white blood count at diagnosis and cytogenetics). Whether inhibiting c-kit in patients with AML will alter prognosis is the basis of ongoing clinical trials.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results